The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
It is anticipated that 548 subjects will be recruited from approximately 27 centres in South
Korea.
This is an investigator-sponsored, double-blind, placebo-controlled, randomized, multi-centre
study to assess the effects of rosuvastatin 20 mg compared to placebo in acute ischemic
stroke patients, with the first dose within 18 hours after baseline MRI and continued
treatment for 14 days.
Subjects will be male or female, over 20 years, with diagnosis of acute ischemic stroke with
baseline MRI, and who are either statin-naïve or untreated with statin for the previous 3
months.
The objective would be to compare the recurrence rate of ischemic stroke by comparing the
imaging parameters during 14 days of treatment and clinical improvement as defined by percent
improvement based on NIHSS scores measurements at baseline, 5 days and 14 days of treatment.